Skip to main content

Treatment Clinical Trials for Melanoma

Review the melanoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 188

Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
RAPA-201 Therapy of Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab for the Treatment of Stage II-III Melanoma
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
RP1 for the Treatment of Melanoma Undergoing Sentinel Lymph Node Biopsy
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients with Solid Tumor Cancers Being Treated with Standard of Care Checkpoint Inhibitors
Status: Active
Location: 5 locations
Intralesional Influenza Vaccine for the Treatment of Stage I-III and IV Melanoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Memory-Like Natural Killer Cell Therapy with Interlekin-2, Nivolumab, and Relatlimab for the Treatment of Patients with Advanced or Metastatic Melanoma after Progression on Checkpoint Inhibitors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Pembrolizumab with or without Metformin in Treating Patients with Stage III-IV Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
CBL0137 in Combination with Ipilimumab and Nivolumab for the Treatment of Stage III-IV Metastatic, Unresectable, or Recurrent Melanoma
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Tetanus Diphtheria Vaccine or Polio Boost Vaccine for Increasing Response to Immune Checkpoint Inhibitor Therapy in Patients with Advanced or Metastatic Melanoma
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Ulixertinib and Palbociclib in Treating Patients with Advanced or Refractory Solid Tumors or Metastatic Pancreatic Cancer or Metastatic Melanoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Intravenous and Intrathecal Nivolumab or Nivolumab/Relatlimab in Treating Patients with Leptomeningeal Disease
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
RNA-Lipid Particle Vaccine for the Treatment of Early Melanoma Recurrence after Anti-PD-1 Antibody Therapy or Uresectable or Metastatic Soft Tissue Sarcoma
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Alpelisib and Pembrolizumab for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Melanoma or Triple Negative Breast Cancer, SELENA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Status: Active
Location: 2 locations
PRAME-TCR-NK Cells for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Recurrent and/or Refractory Melanoma, PRAMETIME-Mel Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Stereotactic Body Radiation Therapy with Nivolumab and BMS986253 for the Treatment of Multiple Metastases in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin